FAP and neoplasm: Clinical data reveal three key benefits compared to its 68Ga counterpart: (i) enhanced therapeutic profile, with higher tumour-to-background ratios (3.5:1 vs. 2.1:1 at 24 h), (ii) improved safety, grade 1–2 adverse events only (vs. Grade 3 in 12% with 68Ga-FAP-2286), and better clinical efficacy, 62% reduction in metastatic burden (RECIST 1.1), 45% objective tumour size reduction, and 78% pain score improvement [123].